Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.

Literature DB >> 24846499

Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.

Oliver FitzGerald¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2014 PMID： 24846499 DOI： 10.1038/nrrheum.2014.77

Source DB: PubMed Journal: Nat Rev Rheumatol ISSN： 1759-4790 Impact factor: 20.543

× No keyword cloud information.

5 in total

Review 1. PDE4 inhibitors: a review of current developments (2005 - 2009).

Authors: Lluís Pagès; Amadeu Gavaldà; Martin D Lehner
Journal: Expert Opin Ther Pat Date: 2009-11 Impact factor: 6.674

2. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

Authors: Georg Schett; Jurgen Wollenhaupt; Kim Papp; Rik Joos; Jude F Rodrigues; Adele R Vessey; ChiaChi Hu; Randall Stevens; Kurt L de Vlam
Journal: Arthritis Rheum Date: 2012-10

3. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors: P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal: Br J Pharmacol Date: 2009-12-24 Impact factor: 8.739

4. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

Authors: Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervolino; Francesco Caso; Alessandro Sanduzzi; Ennio Lubrano; Antonio Del Puente; Raffaele Scarpa
Journal: Clin Rheumatol Date: 2010-04 Impact factor: 2.980

5. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103

5 in total

4 in total

Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.

Review 1. PDE4 inhibitors: a review of current developments (2005 - 2009).

2. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

3. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

4. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.

5. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Review 1. Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Review 2. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

3. Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury.

4. Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8).